Skip to main content
SpringerLink
Log in

Molecular and pharmacologic targeting of angiogenesis factors — the example of pleiotrophin

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Polypeptide growth factors contribute to the development and maintenance of normal tissues and are essential for the growth and metastasis of solid tumors. During tumor progression these factors function as autocrine stimulators of tumor cells and/or serve to recruit stromal tissue and blood supply to the expanding tumor. In particular, tumor-induced angiogenesis appears to be significant not only for local tumor growth but also for metastasis to distant organ sites. We purified several years ago the heparinbinding growth factor pleiotrophin (PTN) from the supernatants of human breast cancer cells and demonstrated that PTN can serve as an angiogenesis factor. We found the gene expressed in a number of human tumor cell lines as well as in human tumor tissues. Here we present different approaches to inhibit production and function of this growth factor. Finally we discuss how the experience from this growth factor can be applied to improve our understanding of the role of other factors thought to contribute to tumor angiogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271–280, 1991

    Google Scholar 

  2. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327–336, 1991

    Google Scholar 

  3. Rodeck U, Herlyn M: Growth factors in melanoma. Cancer Metastasis Rev 10:89–101, 1991

    Google Scholar 

  4. Folkman J, Klagsbrun M: Angiogenic factors. Science 235:442–447, 1987

    Google Scholar 

  5. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356–360, 1994

    Google Scholar 

  6. Wellstein A: Why monitor angiogenic factors in patients' urine? [editorial; comment]. J Natl Cancer Inst 86:328–329, 1994

    Google Scholar 

  7. Böhlen P, Kovesdi I: HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function. Prog Growth Factor Res 3:143–157, 1991

    Google Scholar 

  8. Fang WJ, Hartmann N, Chow D, Riegel AT, Wellstein A: Pleiotrophin stimulates fibroblasts, endothelial and epithelial cells, and is expressed in human cancer. J Biol Chem 267:25889–25897, 1992

    Google Scholar 

  9. Czubayko F, Riegel AT, Wellstein A: Ribozymetargeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 269:21358–21363, 1994

    Google Scholar 

  10. Courty J, Dauchel MC, Caruelle D, Nguyen TT, Barritault D: Purification and characterization of a new endothelial cell growth factor named HARP (Heparin Affin Regulatory Peptide) [abstract]. J Cell Biochem 15F: Abstr 221, 1991

    Google Scholar 

  11. Courty J, Dauchel MC, Caruelle D, Perderiset M, Barritault D: Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem Biophys Res Commun 180:145–151, 1991

    Google Scholar 

  12. Kovesdi I, Fairhurst JL, Kretschmer PJ, Böhlen P: Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins. Biochem Biophys Res Commun 172:850–854, 1990

    Google Scholar 

  13. Huber D, Gautschi-Sova P, Böhlen P: Amino-terminal sequences of a novel heparin-binding protein from human, bovine, rat, and chick brain: high interspecies homology. Neurochem Res 15:435–439, 1990

    Google Scholar 

  14. Kuo MD, Oda Y, Huang JS, Huang SS: Amino acid sequence and characterization of a heparin-binding neurite-promoting factor (p18) from bovine brain. J Biol Chem 265:18749–18752, 1990

    Google Scholar 

  15. Rauvala H: An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J 8:2933–2941, 1989

    Google Scholar 

  16. Merenmies J, Rauvala H: Molecular cloning of the 18-kDa growth-associated protein of developing brain. J Biol Chem 265:16721–16724, 1990

    Google Scholar 

  17. Milner PG, Li YS, Hoffman RM, Kodner CM, Siegel NR, Deuel TF: A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem Biophys Res Commun 165:1096–1103, 1989

    Google Scholar 

  18. Tezuka K, Takeshita S, Hakeda Y, Kumegawa H, Kikuno R, Hashimoto-Gotoh T: Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblast and brain tissues. Biochem Biophys Res Commun 173:246–251, 1990

    Google Scholar 

  19. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, Milbrandt J, Deuel TF: Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 250:1690–1694, 1990

    Google Scholar 

  20. Vanderwinden JM, Mailleux P, Schiffmann SN, Vanderhaeghen JJ: Cellular distribution of the new growth factor pleiotrophin (HB- GAM) mRNA in developing and adult rat tissues. Anat Embryol (Berl) 186:387–406, 1992

    Google Scholar 

  21. Bloch B, Normand E, Kovesdi I, Böhlen P: Expression of the HBNF (heparin-binding neurite-promoting factor) gene in the brain of fetal, neonatal and adult rat: an in situ hybridization study. Brain Res Dev Brain Res 70:267–278, 1992

    Google Scholar 

  22. Wanaka A, Carroll SL, Milbrandt J: Developmentally regulated expression of pleiotrophin, a novel heparin binding growth factor, in the nervous system of the rat. Brain Res Dev Brain Res 72:133–144, 1993

    Google Scholar 

  23. Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, Sasse J, Riegel AT, Lippman ME: A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem 267:2582–2587, 1992

    Google Scholar 

  24. Hampton BS, Marshak DR, Burgess WH: Structural and functional characterization of full-length heparin-binding growth associated molecule. Mol Biol Cell 3:85–93, 1992

    Google Scholar 

  25. Raulo E, Julkunen I, Merenmies J, Pihlaskari R, Rauvala H: Secretion and biological activities of heparin-binding growth-associated molecule. J Biol Chem 267:11408–11416, 1992

    Google Scholar 

  26. Takamatsu H, Itoh M, Kimura M, Gospodarowicz D, Amann E: Expression and purification of biologically active human OSF-1 inEscherichia coli. Biochem Biophys Res Commun 185:224–230, 1992

    Google Scholar 

  27. Laaroubi K, Delbe J, Vacherot F, Desgranges P, Tardieu M, Jaye M, Barritault D, Courty J: Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 10: 89–98, 1994

    Google Scholar 

  28. Hulmes JD, Seddon AP, Decker MM, Böhlen P: Comparison of the disulfide bond arrangements of human recombinant and bovine brain heparin binding neurite-promoting factors. Biochem Biophys Res Commun 192:738–746, 1993

    Google Scholar 

  29. Lai SP, Czubayko F, Riegel AT, Wellstein A: Structure of the human heparin-binding growth factor gene pleiotrophin. Biochem Biophys Res Commun 187:1113–1122, 1992

    Google Scholar 

  30. Li YS, Hoffman RM, Le Beau MM, Espinosa R, Jenkins NA, Gilbert DJ, Copeland NG, Deuel TF: Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization. J Biol Chem 267:26011–26016, 1992

    Google Scholar 

  31. Milner PG, Shah D, Veile R, Donis-Keller H, Kumar BV: Cloning, nucleotide sequence and chromosome localization of the human pleiotrophin gene. Biochemistry 31:12023–12028, 1992

    Google Scholar 

  32. Lai S, Schulte AM, Wellstein A, Riegel AT: An additional 5'-upstream exon exists in the human pleiotrophin-encoding gene. Gene 153:301–302, 1995

    Google Scholar 

  33. Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG: Autocrine growth stimulation by secreted Kaposi's fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1:63–71, 1990

    Google Scholar 

  34. Chauhan AK, Li YS, Deuel TF: Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc Natl Acad Sci USA 90:679–682, 1993

    Google Scholar 

  35. Fang WJ, Wellstein A: The heparin-binding growth factor pleiotrophin supports tumor growth and metastasis. 1994 (unpublished)

  36. Dickson RB, McManaway ME, Lippman ME: Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232:1540–1543, 1986

    Google Scholar 

  37. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428, 1987

    Google Scholar 

  38. Huff KK, Knabbe C, Lindsey R, Kaufman D, Bronzert D, Lippman ME, Dickson RB: Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol Endocrinol 2: 200–208, 1988

    Google Scholar 

  39. Dickson RB, Huff KK, Spencer EM, Lippman ME: Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 118:138–142, 1986

    Google Scholar 

  40. Dickson R, Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29–43, 1987

    Google Scholar 

  41. Wellstein A, Lippman ME: Fibroblast growth factors and breast cancer.In: Broder S (ed) Molecular Foundations of Oncology. Williams and Wilkins, Baltimore, 1991, pp 403–418

    Google Scholar 

  42. Clarke R, Dickson RB, Lippman ME: Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12: 1–23, 1992

    Google Scholar 

  43. Gibson DF, Gottardis MM, Jordan VC: Sensitivity and insensitivity of breast cancer to tamoxifen. J Steroid Biochem Mol Biol 37:765–770, 1990

    Google Scholar 

  44. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844, 1993

    Google Scholar 

  45. Fidler IF, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185–188, 1994

    Google Scholar 

  46. Folkman J: Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 9:171–174, 1990

    Google Scholar 

  47. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267: 10931–10934, 1992

    Google Scholar 

  48. Folkman J, Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 313:355–364, 1992

    Google Scholar 

  49. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ: Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 268:4675–4683, 1993

    Google Scholar 

  50. Tyrrell DJ, Ishihara M, Rao N, Horne A, Kiefer MC, Stauber GB, Lam LH, Stack RJ: Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 268:4684–4689, 1993

    Google Scholar 

  51. Wellstein A, Zugmaier G, Califano JA III, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83:716–720, 1991

    Google Scholar 

  52. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockade by PPS of tumor growth in animals. J Natl Cancer Inst 84: 1716–1724, 1992

    Google Scholar 

  53. Parker BW, Swain SM, Zugmaier G, Lippman ME, Wellstein A: Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J Natl Cancer Inst 85:1068–1073, 1993

    Google Scholar 

  54. Mason IJ: The ins and outs of fibroblast growth factors. Cell 78:547–552, 1994

    Google Scholar 

  55. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents — is the bullet really magical? Science 261:1004–1012, 1993

    Google Scholar 

  56. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333–335, 1994

    Google Scholar 

  57. Colley KJ, Wellstein A: Antisense oligonucleotides of pleiotrophin. Patent application 8/276,330: 1994

    Google Scholar 

  58. Colley KJ, Sale EB, Riegel AT, Wellstein A: Antisense oligonucleotides inhibit pleiotrophin action in vitro and in vivo. Submitted

  59. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR: Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence ofTetrahymena. Cell 31:147–157, 1982

    Google Scholar 

  60. Uhlenbeck OC: A small catalytic oligoribonucleotide. Nature 328:596–600, 1987

    Google Scholar 

  61. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334:585–591, 1988

    Google Scholar 

  62. Cameron FH, Jennings PA: Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 86:9139–9143, 1989

    Google Scholar 

  63. Symons RH: Small catalytic RNAs. Annu Rev Biochem 61:641–671, 1992

    Google Scholar 

  64. Pyle AM: Ribozymes: a distinct class of metalloenzymes. Science 261:709–714, 1993

    Google Scholar 

  65. Zuker M, Stiegler P: Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res 9:133–148, 1981

    Google Scholar 

  66. McCall MJ, Hendry P, Jennings PA: Minimal sequence requirements for ribozyme activity. Proc Natl Acad Sci USA 89:5710–5714, 1992

    Google Scholar 

  67. Sheldon CC, Symons RH: Mutagenesis analysis of a self-cleaving RNA. Nucleic Acids Res 17:5679–5685, 1989

    Google Scholar 

  68. Czubayko F, Wellstein A: Gene dosing of pleiotrophin reveals growth factor-dependent tumor angiogenesis and metastasis. Submitted

Download references

Author information

Authors and Affiliations

  1. Lombardi Cancer Center, Georgetown University, 3970 Reservoir Road N.W., 20007, Washington D.C., USA

    Frank Czubayko, Anke M. Schulte, Shani C. Missner, Susie S. Hsieh, Kenneth J. Colley & Anton Wellstein

Authors
  1. Frank Czubayko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anke M. Schulte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shani C. Missner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susie S. Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth J. Colley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anton Wellstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czubayko, F., Schulte, A.M., Missner, S.C. et al. Molecular and pharmacologic targeting of angiogenesis factors — the example of pleiotrophin. Breast Cancer Res Tr 36, 157–168 (1995). https://doi.org/10.1007/BF00666037

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666037

Key words

Search

Navigation